[The Integrated Approach to Improving Efficiency and Safety of Anticoagulation Therapy in Patients With Prosthetic Mitral Valve].

AIM To assess advantages of integrated approach to improvement of efficiency and safety of warfarin therapy after heart valve replacement. MATERIALS AND METHODS We included in this study 118 patients who had undergone simultaneous mitral valve replacement and maze procedure. Group 1 patients (n=37) underwent just sinus rhythm restoration, group 2 patients (n=54) underwent sinus rhythm restoration and participated in a patient education program, group 3 patients (n=27) underwent sinus rhythm restoration, participated in a patient education program, and were subjected to pharmacogenetic testing for warfarin sensitivity. In examination of patients we used clinical, demographic, and instrumental methods. Estimation of the time in the therapeutic range (TTR) of an international normalized ratio (INR) was used as a measure of warfarin therapy quality, and the Kaplan-Meier method was applied for analysis of hemorrhagic and thrombotic complications. RESULTS TTR was 42 % in group 1, 68 % in group 2 (p=0.0327), and 82 % in group 3 (p=0.0019). Application of integrated approach was associated with absence of hemorrhagic and thrombotic complications within one year after heart valve replacement. CONCLUSION The integrated approach comprising restoration of sinus rhythm, patient education, and pharmacogenetic testing for warfarin sensitivity was associated with improved anticoagulation control, and prevention of hemorrhagic and thrombotic complications.

[1]  Максимов Сергей Алексеевич,et al.  Группировка регионов Российской Федерации по соотношению фактической и смоделированной (по социально-экономическим показателям) сердечно-сосудистой смертности , 2017 .

[2]  Вячеслав Алексеевич Зеленцов,et al.  Методология создания и применения интеллектуальных информационных технологий наземно-космического мониторинга сложных объектов , 2014 .

[3]  E. V. Gorbunova,et al.  ВОЗМОЖНОСТИ ИСПОЛЬЗОВАНИЯ ФАРМАКОГЕНЕТИЧЕСКОГО ПОДХОДА ДЛЯ КОРРЕКЦИИ АНТИКОАГУЛЯНТНОЙ ТЕРАПИИ У БОЛЬНЫХ С ПРОТЕЗАМИ КЛАПАНОВ СЕРДЦА , 2013 .

[4]  G. Lip,et al.  Cardioversion for atrial fibrillation in current European practice: results of the European Heart Rhythm Association survey. , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[5]  A. Natale,et al.  Advances in Catheter Ablation: Atrial Fibrillation Ablation in Patients With Mitral Mechanical Prosthetic Valve , 2012, Current cardiology reviews.

[6]  M. Meyer,et al.  Warfarin therapeutic monitoring: is 70% time in the therapeutic range the best we can do? , 2012, Journal of clinical pharmacy and therapeutics.

[7]  Лепахин Владимир Константинович,et al.  Экспертиза оценки отношения ожидаемой пользы к возможному риску применения лекарственных средств , 2012 .

[8]  А. Л. Шестаков,et al.  Хирургическое лечение заболеваний гастроэзофагеальной области из лапароскопического доступа , 2012 .

[9]  Барбараш Ольга Леонидовна,et al.  Оценка эффективности обучающей программы для пациентов с протезированными клапанами сердца , 2012 .

[10]  Dhanunjaya R. Lakkireddy,et al.  Radiofrequency ablation of atrial fibrillation in patients with mitral or aortic mechanical prosthetic valves: a feasibility, safety, and efficacy study. , 2011, Heart rhythm.

[11]  Астапов Дмитрий Александрович,et al.  Биопротезы клапанов сердца в России: опыт трех клиник , 2011 .

[12]  A. Ragulin.  Случай из КлиничеСКой праК тиКи , 2011 .

[13]  T. Imaizumi,et al.  Long-term results of the maze procedure on left ventricular function for persistent atrial fibrillation associated with mitral valve disease , 2011, Heart and Vessels.

[14]  S. Yun,et al.  Mitral valve replacement with or without a concomitant Maze procedure in patients with atrial fibrillation , 2010, Heart.

[15]  Jenine K. Harris,et al.  Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy , 2010, Journal of thrombosis and haemostasis : JTH.

[16]  Сиротин Борис Залманович,et al.  Цифровая видеобиомикроскопия микроциркуляторного русла конъюнктивы как метод исследования влияния фармакологических препаратов в клинике внутренних болезней , 2010 .

[17]  S. Yusuf,et al.  Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range , 2008, Circulation.

[18]  J. Lelakowski,et al.  Efficacy of intra-operative radiofrequency ablation in patients with permanent atrial fibrillation undergoing concomitant mitral valve replacement. , 2008, Kardiologia polska.

[19]  А. Н. Овсянникова,et al.  Поражение головного мозга и изменения церебральной гемодинамики у больных с клапанными пороками сердца , 2008 .

[20]  Gregory W Albers,et al.  Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. , 2007, Archives of internal medicine.

[21]  He Xiu.  Health education of patients with hypertension , 2004 .

[22]  Zhai Hong.  Health Education for Patients with Hypertension , 2003 .

[23]  J. Gurwitz,et al.  Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. , 2001, Archives of internal medicine.

[24]  J. Hirsh,et al.  Managing oral anticoagulant therapy. , 2001, Chest.

[25]  F R Rosendaal,et al.  A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.